Thrombolytic therapy for acute transmural myocardial infarction. Intracoronary versus intravenous
- PMID: 6496548
- DOI: 10.1016/0002-9343(84)90543-6
Thrombolytic therapy for acute transmural myocardial infarction. Intracoronary versus intravenous
Abstract
The application of coronary angiography in coordination with streptokinase administration directly into the occluded coronary artery has served to focus attention on the clinical potential of such therapy. About 75 percent of patients with acute transmural myocardial infarction have been shown to have reperfusion after intracoronary administration of streptokinase. However, the data do not prove that the beneficial effect required regional perfusion. Analysis of biochemical data suggests that the active agent was not confined to the locale of the thrombus, but in fact circulated in significant concentration; furthermore, systemic (intravenous) treatment resulted in reperfusion of a significant proportion (50 percent) of coronary arteries as well. Comparative studies are needed to critically compare angiographic results after regional or systemic therapy and also to assess the impact of reperfusion on possible reduction in long-term morbidity and mortality. Although intracoronary therapy appears to be more effective for inducing reperfusion, intravenous therapy has the potential for greater clinical impact, since it can be instituted more quickly after the onset of symptoms and does not require specialized cardiac catheterization facilities.
Similar articles
-
Thrombolytic therapy of acute myocardial infarction.Curr Probl Cardiol. 1983 Dec;8(9):1-47. doi: 10.1016/0146-2806(83)90045-2. Curr Probl Cardiol. 1983. PMID: 6661925
-
Intravenous versus intracoronary streptokinase for acute transmural myocardial infarction.Cathet Cardiovasc Diagn. 1984;10(4):319-27. doi: 10.1002/ccd.1810100403. Cathet Cardiovasc Diagn. 1984. PMID: 6488304
-
Quantitative coronary angiography during intracoronary streptokinase in acute myocardial infarction: how long to continue thrombolytic therapy?Cathet Cardiovasc Diagn. 1983;9(1):9-18. doi: 10.1002/ccd.1810090103. Cathet Cardiovasc Diagn. 1983. PMID: 6403248
-
Systemic versus intracoronary streptokinase infusion in the treatment of acute myocardial infarction.J Am Coll Cardiol. 1983 May;1(5):1254-61. doi: 10.1016/s0735-1097(83)80137-5. J Am Coll Cardiol. 1983. PMID: 6339593 Review.
-
Coronary thrombolysis for evolving myocardial infarction.Drugs. 1984 Nov;28(5):465-83. doi: 10.2165/00003495-198428050-00004. Drugs. 1984. PMID: 6391890 Review.
Cited by
-
Tissue-type plasminogen activator. A review of its pharmacology and therapeutic use as a thrombolytic agent.Drugs. 1989 Sep;38(3):346-88. doi: 10.2165/00003495-198938030-00003. Drugs. 1989. PMID: 2509190 Review.
-
Dose-ranging studies of anisoylated plasminogen streptokinase activator complex. Studies in healthy volunteers and in patients with acute myocardial infarction.Drugs. 1987;33 Suppl 3:124-32. doi: 10.2165/00003495-198700333-00020. Drugs. 1987. PMID: 3315577
-
Streptokinase, urokinase, and tissue plasminogen activator: pharmacokinetics, relative advantages, and methods for maximizing rates and consistency of lysis.Cardiovasc Intervent Radiol. 1986;9(5-6):236-44. doi: 10.1007/BF02577952. Cardiovasc Intervent Radiol. 1986. PMID: 3100038
-
Recent clinical developments in thrombolysis in acute myocardial infarction.Drugs. 1987;33 Suppl 3:22-32. doi: 10.2165/00003495-198700333-00004. Drugs. 1987. PMID: 3315595 Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical